193 related articles for article (PubMed ID: 17218850)
21. Molecular imaging in the management of cervical cancer.
Lai CH; Yen TC; Ng KK
J Formos Med Assoc; 2012 Aug; 111(8):412-20. PubMed ID: 22939658
[TBL] [Abstract][Full Text] [Related]
22. Role of PET in gynecologic malignancy.
Grigsby PW
Curr Opin Oncol; 2009 Sep; 21(5):420-4. PubMed ID: 19553814
[TBL] [Abstract][Full Text] [Related]
23. [Role of [18F]-fluorodeoxyglucose positron emission tomography for the initial detection, staging, search for recurrences and restaging of gynaecological and breast cancers].
Grahek D; Barranger E; Daraï E; Uzan S; Talbot JN
Gynecol Obstet Fertil; 2005 Jun; 33(6):371-81. PubMed ID: 15927502
[TBL] [Abstract][Full Text] [Related]
24. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer.
Avril N; Sassen S; Schmalfeldt B; Naehrig J; Rutke S; Weber WA; Werner M; Graeff H; Schwaiger M; Kuhn W
J Clin Oncol; 2005 Oct; 23(30):7445-53. PubMed ID: 16157939
[TBL] [Abstract][Full Text] [Related]
25. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
Yen RF; Sun SS; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544
[TBL] [Abstract][Full Text] [Related]
26. Surgical and radiologic staging of cervical cancer.
Lai CH; Yen TC; Ng KK
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):15-20. PubMed ID: 19952745
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of gynecologic cancer with MR imaging, 18F-FDG PET/CT, and PET/MR imaging.
Lee SI; Catalano OA; Dehdashti F
J Nucl Med; 2015 Mar; 56(3):436-43. PubMed ID: 25635136
[TBL] [Abstract][Full Text] [Related]
28. When and how often should PET scans be performed in the management of cervical cancer?
Lai CH; Yen TC
Expert Rev Anticancer Ther; 2010 Jul; 10(7):983-6. PubMed ID: 20645685
[No Abstract] [Full Text] [Related]
29. PET-imaging in tumors of the reproductive trac.
Reinhardt MJ; Matthies A; Biersack HJ
Q J Nucl Med; 2002 Jun; 46(2):105-12. PubMed ID: 12114873
[TBL] [Abstract][Full Text] [Related]
30. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
[TBL] [Abstract][Full Text] [Related]
31. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
32. Defining the priority of using 18F-FDG PET for recurrent cervical cancer.
Yen TC; See LC; Chang TC; Huang KG; Ng KK; Tang SG; Chang YC; Hsueh S; Tsai CS; Hong JH; Lin CT; Chao A; Ma SY; Lin WJ; Fu YK; Fan CC; Lai CH
J Nucl Med; 2004 Oct; 45(10):1632-9. PubMed ID: 15471826
[TBL] [Abstract][Full Text] [Related]
33. The role of F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) in the screening of cervical cancer: a literature review.
Guo F; Yang R; Tian J; Fan L
Cell Biochem Biophys; 2014 Jun; 69(2):197-201. PubMed ID: 24272282
[TBL] [Abstract][Full Text] [Related]
34. PET imaging in gynecologic malignancies.
Kumar R; Alavi A
Radiol Clin North Am; 2004 Nov; 42(6):1155-67, ix. PubMed ID: 15488564
[TBL] [Abstract][Full Text] [Related]
35. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma.
Schwarz JK; Siegel BA; Dehdashti F; Grigsby PW
JAMA; 2007 Nov; 298(19):2289-95. PubMed ID: 18029833
[TBL] [Abstract][Full Text] [Related]
36. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.
Chung HH; Jo H; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
Gynecol Oncol; 2007 Mar; 104(3):529-34. PubMed ID: 17049971
[TBL] [Abstract][Full Text] [Related]
37. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
38. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome.
Grigsby PW; Siegel BA; Dehdashti F; Rader J; Zoberi I
J Clin Oncol; 2004 Jun; 22(11):2167-71. PubMed ID: 15169804
[TBL] [Abstract][Full Text] [Related]
39. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
40. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
